CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

The medical promise of CRISPR gene editing can be seen most easily in current research on oral cancer, which affects more than 50,000 Americans every year. An increasing challenge in the treatment ...

Scientists around the world are already using the powerful new CRISPR technique to treat disease, modify plants and animals, and even create designer babies. Here's everything you need to know.

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

In this Revvity GENCast episode 2, experts will discuss applications of gene editing to improve scientists’ understanding of the relationship between variant and disease in functional genomics studies ...

Collaborating with CRISPR-Cas9 co-inventor Jennifer Doudna and Jill Banfield at UC Berkeley, Steven Jacobsen, a distinguished professor of molecular, cell and developmental biology at UCLA ...

Crispr Therapeutics is an emerging gene editing ... stage portfolio and a range of potential outcomes. The narrow moat definition states that excess normalized returns must more likely than ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The US Food and Drug Administration has approved a type of CRISPR gene-edited pig for human consumption. And now a type of illness-resistant pig could soon join their ranks. British company Genus ...

At the upcoming annual meeting of the American Society of Gene and Cell Therapy, scientists from Huidagene Therapeutics will share an update on the development of their CRISPR-high-fidelity(hf ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces ...